文献速递泌尿男性生殖肿瘤

单次立体定向体部放疗治疗局限性前列腺癌的非随机临床试验

Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2026-01-01

这项多中心单臂前瞻性1/2期非随机临床试验纳入45例低中危局限性前列腺癌患者,给予19 Gy单次尿道保护SBRT,中位随访55.3个月,3年生化无复发生存率为92.9%,达到主要终点,3级及以上不良事件罕见。

要点

  • 19 Gy单次SBRT的3年bRFS为92.9%,达到预设主要终点。
  • 3年2级GU和GI不良事件分别仅9.8%和4.9%,仅1例3级直肠炎。
  • 2级及以上勃起功能障碍从基线21.4%升至3年38.4%。

核心结论

  • 单次19 Gy尿道保护SBRT在低中危局限性前列腺癌中达到主要终点,3年bRFS为92.9%。
  • 3年2级GU和GI不良事件分别低于10%和5%,安全性可接受。

研究设计与样本

  • 多中心、单臂、前瞻性、1/2期非随机临床试验,纳入低或中危、ISUP分级分组1或2、移行区无显著肿瘤的局限性前列腺癌男性。
  • 2017至2022年在欧洲和美国5个学术中心招募,共45例患者入组(中位年龄72岁,范围60-82岁),43例按方案治疗。

主要发现

  • 中位随访55.3个月(IQR 49.9-60.7)后,估计3年bRFS为92.9%(95%CI 85.4%-100%),达到主要终点。
  • 3年时2级GU不良事件见于4例(9.8%),2级GI不良事件见于2例(4.9%),仅1例在12个月时出现3级直肠炎。
  • 2级及以上勃起功能障碍从基线42例中9例(21.4%)增至3年39例中15例(38.4%)。
  • EPIC评分中GU和性功能评分达到最小临床重要变化的分别有6例(14%)和12例(28%),GI困扰评分影响极小。

关键数值与推荐

  • 主要终点为3年bRFS,预设期望值96%包含在95%CI内。
  • 干预为19 Gy单次前列腺SBRT,采用尿道保护和分次内运动控制。

临床怎么用

  • 对于低中危局限性前列腺癌患者,单次19 Gy尿道保护SBRT可能作为缩短疗程的治疗选择。
  • 治疗前需评估尿道保护与分次内运动控制技术可行性,并向患者说明性功能下降风险。

局限性

  • 单臂非随机设计,样本量较小(45例入组,43例治疗)。
  • 随访时间尚不足以评估长期疾病控制,需更长期随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Stereotactic body radiotherapy (SBRT), most commonly delivered in 5 fractions, is an established treatment option for patients with localized prostate cancer. While efforts to further reduce treatment to fewer than 5 fractions are ongoing, the efficacy and tolerability of single high-dose SBRT remain to be established. OBJECTIVE: To determine in men with localized prostate cancer whether a single-fraction SBRT can be a valid treatment option in terms of biochemical disease control and safety. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, single-arm, prospective, phase 1/2 nonrandomized clinical trial included men with localized prostate cancer at low or intermediate risk, with International Society of Urological Pathology grade group 1 or 2, and without significant tumor in the transitional zone. Participants were recruited between 2017 and 2022 in 5 academic centers in Europe and the US. Data were analyzed between February and May 2026. INTERVENTION: Participants were treated with a 19-Gy single-fraction prostate SBRT with urethra-sparing and intrafraction motion control. MAIN OUTCOMES AND MEASURES: The primary end point was biochemical relapse-free survival (bRFS) at 3 years (expected value of 96% included in the 95% CI). Secondary end points included occurrence of genitourinary (GU), gastrointestinal (GI), and sexual adverse events (AEs) and quality of life (QOL) assessment. RESULTS: Among the 45 patients recruited (median age, 72 [range, 60-82] years), 43 were treated per protocol. After a median follow-up of 55.3 (IQR, 49.9-60.7) months, the estimated 3-year bRFS was 92.9% (95% CI, 85.4%-100%), meeting the primary end point. At 3 years, grade 2 GU and GI AEs were observed in 4 (9.8%) and 2 (4.9%) participants, respectively, with only a grade-3 proctitis observed in 1 patient at month 12. Grade 2 or higher erectile dysfunction increased from 9 of 42 patients (21.4%) at baseline to 15 of 39 (38.4%) at 3 years. A significant minimally clinically important change in Expanded Prostate Cancer Index Composite scores was observed in 6 (14%) and 12 (28%) participants for GU and sexual scores, respectively. The impact in GI bother scores was minimal. CONCLUSIONS AND RELEVANCE: In this multicenter phase 1/2 trial, a single-fraction 19-Gy urethra-sparing SBRT met the primary end point, achieving a 3-year bRFS of 92.9%, with grade 2 GU and GI AEs remaining below 10% and 5%, respectively, at 3 years. Longer follow-up is warranted to assess long-term disease control. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03294889.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Zilli T, Franzese C, Guckenberger M, et al. Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Nonrandomized Clinical Trial. JAMA Oncol. 2026. PMID: 42313395. doi:10.1001/jamaoncol.2026.1886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。